Determinants of COVID-19 vaccine readiness and hesitancy among adults in sub-Saharan Africa.

Publication date: Jul 14, 2023

There is very limited data on the extent and determinants of COVID-19 vaccine hesitancy among adults living in sub-Saharan Africa since the global roll-out of vaccines began in 2021. This multi-country survey sought to investigate COVID-19 vaccine hesitancy and other predictors of readiness to get vaccinated. We conducted surveys among adults residing in nine urban and rural areas in Burkina Faso, Ethiopia, Ghana, Nigeria, and Tanzania in late 2021. Log binomial regression models were used to identify prevalence and factors associated with vaccine hesitancy and beliefs around COVID-19 misinformation. We completed a total of 2,833 interviews. Among all respondents, 9% had never heard of a COVID-19 vaccine, 12% had been vaccinated, and 20% knew someone else who had been vaccinated. The prevalence of vaccine hesitancy varied by country (Ethiopia 29%, Burkina Faso 33%, Nigeria 34%, Ghana 42%, Tanzania 65%), but not by rural or urban context. People who did not think the vaccine was safe or effective, or who were unsure about it, were more likely to be vaccine hesitant. Those who reported they did not have a trusted source of information about the vaccine (aPR: 1. 25, 95% CI: 1. 18,1. 31) and those who thought the vaccine would not be made available to them within the year were more likely to be vaccine hesitant. Women were more likely to be vaccine hesitant (aPR: 1. 31, 95% CI: 1. 19,1. 43) and believe COVID-19 falsehoods (aPR: 1. 05, 95% CI: 1. 02,1. 08). The most commonly believed falsehoods were that the vaccine was developed too fast and that there was not enough information about whether the vaccine was effective or not. Educational campaigns targeted at misinformation and tailored to suit each country are recommended to build trust in COVID-19 vaccines and reduce hesitancy.

Open Access PDF

Concepts Keywords
Fast Adults
Interviews Africa
Nigeria Apr
Rural Ci
Vaccinated Country


Type Source Name
disease VO COVID-19 vaccine
disease IDO country
disease VO vaccinated
disease VO vaccine
disease MESH COVID-19
disease VO effective
disease VO population
drug DRUGBANK Diethylstilbestrol
drug DRUGBANK Coenzyme M
pathway REACTOME Reproduction
disease VO organization
disease MESH Emergency
disease MESH infections
disease VO immunization
disease MESH morbidity
disease VO vaccination
drug DRUGBANK Trestolone
drug DRUGBANK Pentaerythritol tetranitrate
disease MESH measles
pathway KEGG Measles
disease VO USA
disease MESH polio
disease IDO site
drug DRUGBANK Etoperidone
drug DRUGBANK Sodium lauryl sulfate
disease MESH autism
disease MESH infertility
disease VO effectiveness
disease MESH chronic condition
disease MESH hypertension
drug DRUGBANK Hydroxyethyl Starch
disease MESH educational attainment

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *